JP2016530233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530233A5 JP2016530233A5 JP2016524319A JP2016524319A JP2016530233A5 JP 2016530233 A5 JP2016530233 A5 JP 2016530233A5 JP 2016524319 A JP2016524319 A JP 2016524319A JP 2016524319 A JP2016524319 A JP 2016524319A JP 2016530233 A5 JP2016530233 A5 JP 2016530233A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- tumor
- bacterial cell
- nucleic acid
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842749P | 2013-07-03 | 2013-07-03 | |
| US61/842,749 | 2013-07-03 | ||
| PCT/US2014/045086 WO2015002969A1 (en) | 2013-07-03 | 2014-07-01 | Anticancer combinations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087445A Division JP2019167346A (ja) | 2013-07-03 | 2019-05-07 | 抗癌組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530233A JP2016530233A (ja) | 2016-09-29 |
| JP2016530233A5 true JP2016530233A5 (enExample) | 2017-08-03 |
| JP6896420B2 JP6896420B2 (ja) | 2021-06-30 |
Family
ID=52144163
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524319A Active JP6896420B2 (ja) | 2013-07-03 | 2014-07-01 | 抗癌組成物 |
| JP2019087445A Pending JP2019167346A (ja) | 2013-07-03 | 2019-05-07 | 抗癌組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087445A Pending JP2019167346A (ja) | 2013-07-03 | 2019-05-07 | 抗癌組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11141492B2 (enExample) |
| EP (1) | EP3016716B1 (enExample) |
| JP (2) | JP6896420B2 (enExample) |
| KR (1) | KR20160027971A (enExample) |
| CN (1) | CN105407974A (enExample) |
| AU (1) | AU2014284396A1 (enExample) |
| BR (1) | BR112015033053A2 (enExample) |
| CA (1) | CA2917102A1 (enExample) |
| IL (1) | IL243323A0 (enExample) |
| WO (1) | WO2015002969A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519734D0 (en) | 2015-11-09 | 2015-12-23 | Univ Swansea | Cancer therapy |
| JP2019533149A (ja) * | 2016-09-23 | 2019-11-14 | ヴェンタナ メディカル システムズ， インク． | 腫瘍試料中の細胞外マトリックスバイオマーカーをスコアリングするための方法及びシステム |
| CA3069523A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| EP3820992A2 (en) | 2018-07-11 | 2021-05-19 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| SG11202108459QA (en) | 2019-02-27 | 2021-09-29 | Actym Therapeutics Inc | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| WO2020232389A1 (en) * | 2019-05-16 | 2020-11-19 | City Of Hope | Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery |
| AU2020382614B2 (en) | 2019-11-12 | 2025-12-11 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| AU2021324883A1 (en) | 2020-08-12 | 2023-03-23 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| CN113769063B (zh) * | 2021-09-30 | 2024-01-19 | 浙江大学 | 一种多肽ptpr在制备肿瘤免疫治疗药物中的应用 |
| KR102680316B1 (ko) * | 2021-11-01 | 2024-07-01 | 오토텔릭바이오 주식회사 | 안티센스 올리고뉴클레오타이드 |
| EP4429682A2 (en) | 2021-11-09 | 2024-09-18 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| CN115838720A (zh) * | 2022-07-28 | 2023-03-24 | 吉林启众生物科技有限公司 | 一种携带shSTAT3/shPD-L1重组质粒的减毒沙门氏菌载体及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US20050112141A1 (en) * | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| WO2002059300A2 (en) | 2000-12-28 | 2002-08-01 | J & J Research Pty Ltd | Double-stranded rna-mediated gene suppression |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| AU2004218354B2 (en) | 2003-03-05 | 2009-10-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| WO2005018332A1 (en) * | 2003-08-13 | 2005-03-03 | The General Hospital Corporation | Modified microorganisms for anti-cancer therapy |
| EP1986697B1 (en) | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| CN1974759B (zh) * | 2006-07-26 | 2010-06-09 | 吉林大学 | 运载重组质粒的减毒沙门氏菌及其在抗肿瘤中的应用 |
| WO2008036841A2 (en) | 2006-09-22 | 2008-03-27 | Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by rna interference |
| US20080311081A1 (en) * | 2007-06-15 | 2008-12-18 | Johannes Fruehauf | Bacteria mediated gene silencing |
| NZ601248A (en) * | 2008-04-14 | 2014-06-27 | Halozyme Inc | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| WO2012149364A1 (en) * | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
-
2014
- 2014-07-01 AU AU2014284396A patent/AU2014284396A1/en not_active Abandoned
- 2014-07-01 BR BR112015033053A patent/BR112015033053A2/pt not_active Application Discontinuation
- 2014-07-01 CA CA2917102A patent/CA2917102A1/en not_active Abandoned
- 2014-07-01 EP EP14819900.3A patent/EP3016716B1/en active Active
- 2014-07-01 CN CN201480041314.4A patent/CN105407974A/zh active Pending
- 2014-07-01 WO PCT/US2014/045086 patent/WO2015002969A1/en not_active Ceased
- 2014-07-01 JP JP2016524319A patent/JP6896420B2/ja active Active
- 2014-07-01 KR KR1020167001786A patent/KR20160027971A/ko not_active Withdrawn
-
2015
- 2015-12-22 US US14/978,590 patent/US11141492B2/en active Active
- 2015-12-24 IL IL243323A patent/IL243323A0/en unknown
-
2019
- 2019-05-07 JP JP2019087445A patent/JP2019167346A/ja active Pending
-
2021
- 2021-09-17 US US17/478,133 patent/US20220241432A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530233A5 (enExample) | ||
| JP2019167346A5 (enExample) | ||
| Araste et al. | Peptide-based targeted therapeutics: Focus on cancer treatment | |
| Barve et al. | Prostate cancer relevant antigens and enzymes for targeted drug delivery | |
| WO2015154059A3 (en) | Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle | |
| WO2015123576A3 (en) | Targeted nanoparticle compositions and methods of their use to treat obesity | |
| WO2017044894A3 (en) | Cartilage-homing peptides | |
| HK1252759A1 (zh) | 肽寡核苷酸缀合物 | |
| IL275389B2 (en) | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| IL224048B (en) | Antiganic composition comprising whole killed or attenuated pathogenic eschrichia coli ( e.coli) cells for intradermal or subcutaneous administration for treating a human patient for crohn's disease | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| JP2017532343A5 (enExample) | ||
| JP2017514800A5 (enExample) | ||
| JP2016523558A5 (enExample) | ||
| WO2016081835A3 (en) | Targeted structure-specific particulate delivery systems | |
| BR112014027905A2 (pt) | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. | |
| Weintraub et al. | Advances in intravesical therapy for the treatment of non‑muscle invasive bladder cancer | |
| WO2017062615A3 (en) | Combination therapy for the treatment of cancer | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Skalickova et al. | Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer | |
| JP2018509423A5 (enExample) | ||
| JP2019517507A5 (enExample) | ||
| JP2016515123A5 (enExample) |